Skip to main content
. Author manuscript; available in PMC: 2021 Apr 9.
Published in final edited form as: Leukemia. 2015 Nov 5;30(4):789–799. doi: 10.1038/leu.2015.308

Figure 4. Epigenetic role of PRMT5 in repression of miR-29b.

Figure 4.

(A) qRT-PCR analysis measuring reduced miR-29b levels in blood and spleen from THP-1/PRMT5 vs THP-1/EV mice. (B) Expression of mature miR-29b following ectopic expression of PRMT5 in AML blasts. (C) Expression of miR-29b in AML blasts treated with PRMT5-siRNA as measured by quantitative PCR. (D) Time-dependent changes in miR-29b expression in AML cell lines and patient blasts after 24 hours incubation with HLCL-61. (E-G) ChIP assay to assess enrichment of PRMT5 as well as H4R3me2 and H3R8me2 (methylation marks deposited by PRMT5) on the enhancer region of miR-29b. Inhibition of PRMT5 with HLCL-61 resulted in significant decrease of H4R3me2 and PRMT5 localization onto miR-29b enhancer site. PRMT5 overexpression significantly enhanced the localization of H4R3me2 methylation mark at the miR-29b regulatory region.